Cargando…
Facial erythema after the treatment of dupilumab in SLE patient
BACKGROUND: Dupilumab is a receptor antagonist binding to the alpha subunit of the interleukin-4 receptor. Through binding to it, dupilumab inhibits signaling of both IL-4 and IL-13, the representative Th2 biomarkers. Recently, in addition to the treatment effects for atopic dermatitis (AD), there i...
Autores principales: | Jang, Dong Hyek, Lee, Jae In, Bae, Joo Yoon, Jung, Hye Jung, Park, Mi Yeon, Ahn, Jiyoung |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7491356/ https://www.ncbi.nlm.nih.gov/pubmed/32944024 http://dx.doi.org/10.1186/s13223-020-00458-6 |
Ejemplares similares
-
Retrospective Study of Dupilumab Treatment for Moderate to Severe Atopic Dermatitis in Korea: Efficacy and Safety of Dupilumab in Real-World Practice
por: Jang, Dong Hyek, et al.
Publicado: (2020) -
A 52 weeks dupilumab treatment for moderate to severe atopic dermatitis in Korea: long-term efficacy and safety in real world
por: Jang, Dong Hyek, et al.
Publicado: (2021) -
Efficacy of pregabalin for the treatment of chronic pruritus of unknown origin, assessed based on electric current perception threshold
por: Lee, JaeIn, et al.
Publicado: (2020) -
Dupilumab-associated Facial Erythema Successfully Treated With Oral Ivermectin
por: Liane, Javier Gil, et al.
Publicado: (2022) -
Skin Disease in Korean Human Immunodeficiency Virus Patient
por: Jung, Hye Jung, et al.
Publicado: (2019)